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Background and Aims. Long-term use of menopausal hormone therapy, typically in the form of 
estrogen or estrogen + progesterone, can increase the amount of dense breast tissue in women, 
which is associated with breast cancer. These changes are commonly measured using 
mammograms to calculate percent density; higher percent density is also associated with breast 
cancer. Newer methods of mammogram analysis look at spatial texture feature variation; these 
approaches are more sensitive than percent density, however the association between texture 
features and hormone therapy use is not well-documented. This study aims to analyze a specific 
texture feature, the V metric, which is a measure of the standard deviation of greyscale pixel 
intensity values from a mammogram image. We evaluated the V metric and its associations with 
both estrogen and estrogen + progesterone menopausal hormone therapy for durations of less 
than or equal to 5 years as well as more than 5 years. Our goal was to further establish V as a 
sensitive predictive measure of breast cancer. 
 
Methods. This was a retrospective cohort study that used participant data from the Nurses’ 
Health Study I and II. The study included 1,986 postmenopausal women that had available 
mammograms and menopausal hormone therapy use data. From both low and high-resolution 
mammograms, the V metric is computed. To evaluate the outcome variable V, linear mixed 
models were fit, adjusting for age, BMI, race, menopause, family history of breast cancer, 
personal history of benign breast disease, total breastfeeding, age at first birth, parity, age at 
menarche, age at menopause, physical activity, and alcohol intake. Models were then stratified 
by menopause type and percent mammogram density. Sensitivity analyses were conducted with 
the subset of mammograms that were high-resolution. 
 
      1 
 
 
Results. Adjusting for covariates, participants that used estrogen + progesterone for more than 5 
years had significantly higher mean V measures than those that used estrogen or never used 
menopausal hormone therapy. Participants using any form of menopausal hormone therapy for 
any duration had significantly higher mean V measures than never users. 
 
Conclusions. Menopausal hormone therapy is significantly associated with higher mean V 
measures. Various durations of therapy can affect breast tissue physiology, leading to increases 
in dense tissue. This can increase risk of breast cancer. Notably, the V metric may quantify some 
changes that percent mammogram density does not register. Particularly in women that used 
estrogen + progesterone therapy for longer durations, the V metric may be a more accurate 
predictor of breast cancer risk. Additional evaluation of related physiological factors and their 
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As menopause commences, fluctuating hormone levels (most notably estrogen) can lead 
to a wide range of ailments, including hot flashes, sweating, mood changes, and joint/muscle 
pain. In order to alleviate these symptoms, a variety of drug treatments may be prescribed, which 
are collectively known as Menopausal Hormone Therapy (MHT). In most cases, MHT is 
prescribed as a form of estrogen, either independent or in combination with another hormone, 
such as progesterone or, less commonly, testosterone16. The aim of this therapy is to increase 
hormone levels in a manner that can effectively reduce negative symptoms. 
 
While MHT is often helpful in improving the wide range of symptoms and discomforts 
associated with menopause, research has shown that there are also long-term risks associated 
with its use, such as breast cancer1,16. This association varies for specific kinds of MHT- for 
instance, risk has generally been found to be higher among users of combined estrogen + 
progesterone formulations as opposed to estrogen alone14. Further, the relation between MHT 
use and breast cancer risk may be mitigated by other factors, such as parity, increased 
breastfeeding duration, and body mass index (BMI). A general explanation for the impact of 
MHT on breast cancer risk may be estrogen’s diverse hormonal impact on physiology4,14,15. 
Effects of MHT are considerable- notably, findings have shown that MHT affects 
mammographic density, a measure of dense tissue (including milk glands, ducts, and supportive 
tissue) vs. non-dense (fatty) tissue in the breast (denoted as percent mammographic density: 
PMD)10,11. Specifically, MHT has been shown to increase dense tissue, and higher PMD is 
strongly associated with breast cancer risk2,11,15. Research on MHT, as well as PMD, has thus 
proven to be useful in predicting and measuring breast cancer risk. Having access to MHT and 







risk. Fortunately, PMD is a reliable and easily accessible measure; it is derived from the relative 
measure of dense to non-dense tissue in a mammogram image, and many women that have 
undergone MHT have had a mammogram. 
Recently, different approaches to analyzing mammograms have been in development. As 
opposed to considering a relative measure of density, the actual distribution of the dense tissue 
throughout the breast can be quantified. These approaches are referred to as “texture measures”, 
as they are considering the different appearances, or “texture” of dense tissue on a 2-D 
mammogram. These texture measures, like PMD, have been shown to be associated with breast 
cancer risk8,12. However, they are significant because their association exists independently of 
percent density, meaning that they may potentially be another useful predictive tool. One specific 
texture measure, the V metric, was developed using data from 3 different studies at the Mayo 
Clinic10. It considers the variation of grey intensity values across the mammogram, compiling 
them into a summary statistic that has also been shown to be associated with breast cancer risk12. 
 
In the Nurses’ Health Study (NHS) and NHSII, we have shown that the V metric is 
associated with breast cancer risk independent of PMD17. While there is already evidence of 
association between MHT and PMD, it is unknown whether MHT may influence other texture 
measures, such as the V metric. Understanding the relationship between MHT and the V metric 
will be useful for characterizing how MHT may influence breast tissue as it appears on a 






















The NHS and NHS II are longitudinal cohort studies, with start dates in 1976 and 1989, 
respectively. Briefly, at baseline, the NHS enrolled 121,700 female registered nurses (RNs) with 
ages ranging from 30 to 55. NHS II is comprised of 116,429 RNs aged 25 to 42. Participants in 
both studies filled out biennial questionnaires, providing health and medical information, as well 
as behaviors and lifestyle factors. Participants reported any new incidence of disease, including 
breast cancer, in each follow-up questionnaire. 
Of the participants in the main NHS and NHS II studies, individuals in blood and cheek 
cell collection cohorts were selected as controls in a nested case-control study of breast cancer. 
Specifically, 32,826 NHS participants aged 43 to 70 had blood drawn in 1989 or 1990; samples 
were then stored in liquid nitrogen. For NHS II, 29,611 participants aged 32-45 had blood drawn 
between 1996 and 1999, and samples were again stored. Across these breast cancer nested case-
control studies, 1 to 2 controls were matched per breast cancer case. We attempted to collect 
mammograms for all participants in these nested case-control studies as close as possible to the 
time of blood draw date, totaling 2,137 cases and 4,346 controls. 
Analyses were restricted to postmenopausal controls with measured V and key exposure 
covariates. We excluded 1,890 women who indicated they were premenopausal at the time of 
mammogram. From total controls, we also excluded women with missing values for V (n=338), 
MHT status (n=2,013), and age (n=0) or BMI (n=81) at the time of mammogram. Values for 
each missing variable are those missing from the total controls (n=4,346); there was significant 
overlap. After restriction, 1,986 postmenopausal women were included in the analysis, 1,547 









Menopausal hormone therapy use was reported by participants on every biennial 
questionnaire. Using these data, we evaluated the MHT use closest to and prior to the 
mammogram date. Participants were assigned to one of seven categories: “Never used 
menopausal hormones”, “Used them in any form in the past”, “Current use of estrogen for MHT 
for less than 5 years”, “Current use of estrogen for MHT for more than 5 years”, “Current use of 
estrogen and progesterone for MHT for less than 5 years”, “Current use of estrogen and 
progesterone for MHT for more than 5 years”, or “Current use, other” (includes progesterone 
alone, vaginal estrogen or vaginal progesterone, estrogen and testosterone, and other unspecified 
combinations). 
 
The V Metric 
 
The V metric considers grey-scale intensity variation across the mammogram image10. 
To obtain a “V75” V metric measure, the outer 25% of the breast area is eroded in a radial 
direction to eliminate possible error regions- the outer region may not be considered as reliable 
as it is not central to compression paddles during imaging. After erosion of these outer regions, 
the standard deviations of the pixel values within the central region gives the V metric, which 
may be either negative (low) or positive (high). Mammograms included in this analysis were 




To estimate beta coefficients (β) and 95% confidence intervals (CI) for the association 
between MHT status and V measure, a multivariable linear mixed model was used. All covariate 
information was measured at or near time of mammogram and included age (continuous), BMI 







breast cancer (yes/no), personal history of benign breast disease (yes/no), total breastfeeding 
months (less than 1, 1 to 6, 7 to 12, 13 or more), age at first birth (continuous), parity 
(continuous), age at menarche (continuous), age at menopause (continuous), physical activity (0 
to 7.5 hrs/wk, 7.5 to 15 hrs/wk, 15 to 28 hrs/wk, over 28 hrs/wk), and alcohol intake (0g/d, 0.1 to 
4.9g/d, 5.0 to 14.9g/d, >15.0g/d). An initial base model included age and BMI as covariates, as 
both have been shown to be strongly associated with PMD and breast cancer risk8. All covariates 
were considered in the multivariable model, with covariates being selected by significance level, 
while also evaluating overall R2 for each covariate addition/deletion. MHT status, age, and BMI 
were included in all model iterations. From potential models, the model with the lowest Schwartz 
Bayesian information criterion (a measure of overfitting), largest R2, and simultaneous covariate 
p-value significance was chosen. The multivariable model included MHT status, age, BMI, race, 
family history of breast cancer, personal history of benign breast disease, total breastfeeding 
months, age at first birth, and parity. A multivariable + PMD model included PMD as a 
covariate. 
 
Previous studies have indicated clear effects of age and BMI on PMD and texture 
features8,13. However, other factors, including those relating to menopause, have not been 
investigated. To determine whether type of menopause (e.g., natural vs. surgical) was an effect 
modifier, we ran stratified analyses and conducted separate regressions for interaction. 
Additionally, we conducted secondary analyses by categorizing PMD using its median (high 
vs. low). In sensitivity analyses, we evaluated the V metric’s association using high resolution 
















Of 1,986 included women, the mean age at time of mammogram was 58.0, and the mean 
BMI was 26.1. The majority of women were White (95.8%), parous (90.5%), and had no family 
history of breast cancer (88.0%) (Table 1). Roughly half (54.2%) of women indicated natural 
menopause. However, as expected, women that used estrogen only MHT for <5 years and for 5+ 
years had much higher rates of surgical menopause (84.1% and 90.0%). Women using estrogen 
only MHT also had lower average ages for menopause (42.9 and 41.1, respectively), compared 
with never users and users of MHT formulations. 
In the main age-standardized analyses, the mean V metric ranged from -0.43 to 0.07. 
Women that used estrogen + progesterone for less than 5 years had the greatest mean V measure 
(0.07), while women that never used MHT had the lowest (-0.43). In sensitivity analyses, women 
that used estrogen + progesterone for over 5 years had the greatest mean V measure (-0.02), 
while never users again had the lowest (-0.52). PMD was highest among estrogen + progesterone 
<5y users (32.2) and lowest among never users (23.2). Overall, the V metric was positively 
correlated with PMD (Pearson r=0.56). A similar correlation was observed when we limited to 
the high-resolution images only (Pearson r=0.50; N=862). 
 
Menopausal Hormone Therapy 
 
In age and BMI adjusted models, using estrogen only or estrogen + progesterone was 
significantly associated with higher V75 compared with never users. Participants using estrogen+ 
progesterone for <5y had mean V measures 0.36 greater than never users, and estrogen only <5y 
indicated an increase in mean V measure of 0.27. When the age and BMI model was stratified by 







measure increased for estrogen+ progesterone <5y (β=0.47, 95% CI= 0.30 to 0.63), as well as 
for estrogen only >5y and estrogen+ progesterone >5y. When stratified by PMD (low vs. high, 
cutoff at median), the association for estrogen+ progesterone <5y at high PMD was attenuated 
but retained significance (β=0.29, 95% CI= 0.11 to 0.47). 
In the full multivariable models, estrogen only <5y, estrogen+ progesterone <5 years, and 
estrogen + progesterone >5 years had significantly higher mean V measures than never users. 
The largest estimate was estrogen+ progesterone <5y (β=0.28, 95% CI= 0.13 to 0.43). With 
stratification for menopause type, natural menopause indicated significance for estrogen only 
>5y, estrogen + progesterone <5y, and estrogen + progesterone >5y, where estrogen only >5y 
was (β=0.50, 95% CI= 0.17 to 0.84). The full model stratification for PMD did not indicate 
differences in mean V75. 
In the multivariable model + PMD, the mean V75 for estrogen + progesterone <5y was 
significantly greater than the reference (β=0.19, 95% CI= 0.05 to 0.33). Additionally, 
stratification for menopause type yielded significant estimates for natural menopause estrogen+ 
progesterone <5y (β=0.26, 95% CI= 0.10 to 0.42) and estrogen+ progesterone >5y (β=0.26, 
95% CI= 0.08 to 0.44). 
 
MHT: Secondary Analysis 
 
In sensitivity analyses, we restricted to high resolution images (N=862), estimates were 
comparable. Exceptions included the age + BMI model stratification by menopause type; the 
mean V75 high resolution for past MHT users was greater than never users (β=0.35, 95% CI= 
0.11 to 0.58). Additionally, the full model estimate for estrogen only >5y was greater than the 
reference (β=0.24, 95% CI= 0.06 to 0.41), and the full model stratification by menopause type 









Results indicated that longer durations of MHT use were generally associated with higher 
V measures. Specifically, estrogen + progesterone >5y groups in both the age + BMI and the 
adjusted model exhibited significantly higher mean V measures; this effect persisted in 
sensitivity analyses. Notably, after adjusting for PMD, the effect of the estrogen + progesterone 
>5y groups was no longer significant, however the continued effect of the estrogen + 
progesterone <5y group suggests that compared to estrogen alone, estrogen + progesterone may 
have a greater impact on risk, as measured by V metric. Compared to PMD, the V metric may 
therefore be a more sensitive measure for evaluating tissue changes resulting from different 
forms and durations of MHT, as well as potentially subsequent risk of breast cancer. 
The age + BMI model indicated that mean V75 estimates for estrogen only (<5y and >5y) 
and estrogen + progesterone (<5y and >5y) were greater than never users. For those with natural 
menopause in the age + BMI model, estrogen only >5y and estrogen + progesterone (<5y and 
>5y) retained significant estimates. When this model was adjusted for PMD, the estrogen + 
progesterone <5y participants with high PMD had a mean V75 estimate shown to be greater than 
never users. In the multivariable model, the mean V75 estimate for estrogen <5y and estrogen + 
progesterone (<5y and >5y) was greater than for never users. Among natural menopause users, 
estrogen only >5y and estrogen + progesterone (<5y and >5y) had significantly greater mean 
V75 measures. 
The multivariable model adjusted for PMD yielded a greater V75 mean for estrogen + 
progesterone <5y compared to never users. Stratification by menopause gave significant estimates 
for natural menopause estrogen + progesterone (<5y and >5y). Secondary analyses resembled 







gave significantly greater mean V75 (high resolution) estimates for past users, compared to never 
users. These findings support previous research that indicates MHT use in general is associated 
with higher quantities of dense tissue, as measured by PMD or V1,10. 
 
Additionally, our results show that different forms of MHT may have varying impacts. 
Estrogen + progesterone groups generally had higher mean V75 estimates than estrogen only, 
and also showed significant estimates in stratification for natural menopause and high PMD, 
while estrogen only did not. This aligns with findings that highlight the increased risk of breast 
cancer from estrogen + progesterone as compared to only estrogen14. The trend was present in 
secondary analyses for V75 high resolution as well. 
 
Along with the kind of MHT, duration of treatment had an effect on V metric as well. In 
the main analysis, >5y categories were more consistently significant than <5y categories (for 
both estrogen only and estrogen + progesterone). This is exemplified in the age + BMI and 
multivariable models: Almost all estimates of estrogen >5y and estrogen + progesterone >5y are 
significantly higher than never users. This trend is also present in secondary analyses. This 
supports the notion that longer durations of MHT may increase physiological effects, including 
the V metric. 
Results show that the trend between physiological factors (PMD, body composition, 
surgery) and the V metric continues to be evident. Considering that body physiology can be 
greatly affected by endocrines, these analyses support that MHT may have significant hormonal 
impact. After adjustment for PMD and BMI, there was a strong association between MHT users 
and higher mean V75 measures across models, compared to mean V75 in never users. The 
association was mitigated to an extent with the inclusion of relevant breast cancer risk factors in 







further explain variance in the model. Stratification suggests that type of menopause may modify 
the effect, as women that indicated natural menopause consistently had larger estimates for mean 
V75 across all models, compared to surgical menopause. 
PMD was also indicated to be associated with V: Age + BMI models across main and 
secondary analyses had significant estimates. However, several estimates in the multivariable 
model were marginally significant for high PMD, and the multivariable + PMD model yielded 
significant results as well. This, along with the measured correlation between PMD and V, 
supports previous findings that the two measures are associated. This offers more evidence 





The findings indicated that both estrogen and estrogen + progesterone menopausal 
hormone therapy use for either duration significantly increased V measures compared to those 
that had never used therapy. Specifically, estrogen + progesterone showed a stronger association; 
its effect remained after adjustment for percent mammogram density. Results showed that 
treatment durations of more than 5 years generally increased V measures more than treatment 
durations of 5 or less years, however this trend was not universal. 
The study does have limitations. MHT status is self-reported and is therefore subject to 
error. Considering this, trends regarding MHT use that were found have been supported in 
previous literature, specifically that MHT use has decreased, but that estrogen only is still the 
most common approach11. MHT status was evaluated year to year and conflicting responses 
were omitted. Additionally, the majority of participants were white and generalization to other 







However, there are notable strengths to this study. The automation of the texture measure 
V as well as the validity of PMD derived from mammograms both serve to reduce measurement 
error. Further, conducting analyses at higher resolution yielded similar results, which supports 
the reliability of these measures. Stratifying allowed for effect modification to be evaluated and 
effectively identified influential covariates, particularly the association of V independent of 
PMD. We also tested correlation between V and PMD to reinforce previous findings of 
association. Additionally, adjusting for multiple covariates allowed for more accurate estimations 
of variation as explained by our models. 
The derived association between MHT status and the V measure is supported by findings 
that indicate associations between hormonal replacement therapy and mammographic density, 
which show a strong direct relationship, particularly with estrogen. As various texture features 
have been indicated as predictors of percent density, these results further suggest that while a 
correlation may be present between the two measures, the V metric’s predictive ability remains 
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Table 1. Participant Characteristics  
V75 Low 
   MHT Status    
Never (N=702) Past (N=334) Estrogen <5y (N=176) Estrogen >5y (N=351) Est. & Progest. <5y (N=192) Est. & Progest. >5y (N=148) Other (N=83)  
Age at mammogram, years 58.5 (7.7) 62.2 (7.8) 53.1 (6.8) 57.4 (7.8) 54.4 (5.3) 58.3 (7.0) 58.4 (7.5) 
BMI at mammogram 26.7 (5.7) 25.9 (4.9) 26.7 (5.4) 26.0 (5.2) 25.0 (4.4) 25.0 (4.6) 25.4 (4.7) 
Non-white, % 3.3 6.9 2.8 4.0 2.1 5.4 7.2 
Type of menopause        
. 3.9 4.8 1.1 0.6 5.7 4.1 6.0 
Natural 67.8 56.9 14.8 9.4 82.8 73.0 55.4 
Surgical 28.4 38.3 84.1 90.0 11.5 22.0 38.6 
Family history of breast cancer        
No 86.6 83.8 93.2 88.9 94.8 86.5 89.2 
Yes 13.4 16.2 6.8 11.1 5.2 13.5 10.8 
History of benign breast disease        
No 79.3 76.4 76.7 73.2 75.0 75.7 81.9 
Yes 20.7 23.7 23.3 26.8 25.0 24.3 18.1 
Age at menarche, years 12.4 (1.6) 12.5 (1.4) 12.3 (1.7) 12.5 (1.5) 12.3 (1.3) 12.7 (1.5) 12.7 (1.5) 
Age at menopause, years 47.3 (6.6) 46.4 (6.6) 42.9 (7.2) 41.1 (6.6) 48.6 (4.8) 45.7 (6.9) 45.8 (7.0) 
Parity        
Mean parity 3.4 (1.5) 3.2 (1.5) 2.9 (1.4) 2.9 (1.3) 2.9 (1.3) 2.8 (1.3) 3.1 (1.6) 
nulliparous 8.3 7.8 11.4 10.3 11.5 12.8 9.6 
1 5.0 7.8 10.2 11.4 12.5 11.5 7.2 
2 26.2 23.7 30.1 28.8 25.0 29.7 33.3 
3 24.4 29.3 25.6 26.5 26.0 21.6 20.5 
4+ 36.2 31.4 22.7 23.1 25.0 24.3 28.9 
Total breastfeeding        
<1 month 38.2 36.2 34.7 41.3 32.8 33.1 39.8 
1-6 months 20.5 27.5 22.7 21.1 24.0 19.6 16.9 
7-12 months 11.7 9.3 7.4 9.4 13.5 11.5 13.3 
>=13 months 22.1 20.4 25.0 18.8 19.3 23.0 21.7 
. 7.6 6.6 10.2 9.4 10.4 12.8 8.4 
Age at first birth, years 25.4 (3.4) 25.3 (3.4) 24.5 (3.2) 24.3 (3.3) 25.0 (3.7) 25.5 (3.8) 25.6 (3.4) 
V75, low -0.43 (0.95) -0.30 (0.93) -0.09 (0.90) -0.22 (0.97) 0.07 (0.95) -0.04 (0.96) -0.24 (0.87) 
V75, high -0.52 (0.90) -0.43 (0.95) -0.29 (0.87) -0.24 (1.00) -0.08 (1.01) -0.02 (0.76) -0.21 (0.89) 
Percent memmographic density 23.18 (17.93) 23.58 (16.93) 30.69 (18.18) 26.54 (16.54) 32.21 (18.63) 29.16 (17.32) 27.56 (18.29) 
 
 
Table 2: Age + BMI Model, Multivariable Model   
            V75 Low             
 Age + BMI     Age + BMI: Natural Menopause   Age + BMI: Surgical Menopause   Age + BMI: Low PMD    Age + BMI: High PMD    
MHT Status Estimate N 95% CI P-value Estimate N 95% CI P-value Estimate N 95% CI P-value Estimate N 95% CI P-value Estimate N 95% CI P-value 
Never 0 (ref) 702    0 (ref) 476    0 (ref) 199    0 (ref) 415    0 (ref) 287    
Past 0.13 334 0.01 0.25 0.036 0.16 190 0.01 0.31 0.034 -0.11 128 -0.33 0.10 0.302 0.05 188 -0.07 0.18 0.919 0.10 146 -0.08 0.27 0.110 
Estrogen <5y 0.27 176 0.12 0.42 <.001 0.26 36 -0.09 0.60 0.146 0.09 148 -0.11 0.28 0.368 0.24 66 0.04 0.44 0.348 0.09 110 -0.10 0.28 0.421 
Estrogen >5y 0.16 351 0.04 0.27 0.007 0.50 33 0.19 0.81 0.002 -0.09 316 -0.26 0.08 0.287 0.03 158 -0.11 0.17 0.338 0.09 193 -0.06 0.24 0.016 
Est + Prog <5y 0.36 192 0.21 0.50 <.001 0.47 159 0.30 0.63 <.001 -0.10 22 -0.50 0.31 0.634 0.22 70 0.02 0.41 0.793 0.29 122 0.11 0.47 0.003 
Est + Prog >5y 0.29 148 0.13 0.45 <.001 0.47 108 0.28 0.65 <.001 -0.33 34 -0.66 0.01 0.054 0.20 63 0.00 0.40 0.023 0.19 85 -0.02 0.40 0.014 
Other 0.11 83 -0.09 0.32 0.283 0.25 46 -0.02 0.51 0.071 -0.12 32 -0.47 0.22 0.484 -0.05 35 -0.31 0.20 0.983 0.04 48 -0.22 0.30 0.183 
P-trend <0.01     <0.01     <0.01     <0.01     <0.01     
                        
 Full Model     Full: Natural Menopause    Full: Surgical Menopause    Full: Low PMD     Full: High PMD     
MHT Status Estimate N 95% CI P-value Estimate N 95% CI P-value Estimate N 95% CI P-value Estimate N 95% CI P-value Estimate N 95% CI P-value 
Never 0 (ref) 702    0 (ref) 476    0 (ref) 199    0 (ref) 415    0 (ref) 287    
Past 0.11 334 -0.02 0.23 0.090 0.15 190 0.00 0.31 0.050 -0.15 128 -0.37 0.08 0.200 0.05 188 -0.08 0.18 0.478 0.07 146 -0.11 0.26 0.437 
Estrogen <5y 0.27 176 0.11 0.43 0.001 0.34 36 -0.04 0.72 0.082 0.09 148 -0.11 0.29 0.387 0.25 66 0.05 0.46 0.016 0.07 110 -0.13 0.28 0.484 
Estrogen >5y 0.15 351 0.03 0.27 0.018 0.50 33 0.17 0.84 0.003 -0.08 316 -0.26 0.09 0.348 0.01 158 -0.13 0.16 0.861 0.07 193 -0.09 0.24 0.383 
Est + Prog <5y 0.28 192 0.13 0.43 <.001 0.38 159 0.21 0.56 <.001 -0.11 22 -0.51 0.29 0.603 0.19 70 -0.01 0.39 0.060 0.19 122 0.00 0.39 0.050 
Est + Prog >5y 0.23 148 0.06 0.40 0.007 0.41 108 0.22 0.61 <.001 -0.36 34 -0.72 0.00 0.047 0.12 63 -0.09 0.33 0.254 0.15 85 -0.07 0.38 0.178 
Other 0.10 83 -0.11 0.31 0.367 0.21 46 -0.06 0.48 0.127 -0.10 32 -0.48 0.27 0.589 -0.05 35 -0.32 0.22 0.706 -0.01 48 -0.29 0.26 0.917 
P-trend <0.01     <0.01     <0.01     <0.01     <0.01     
                     
 Full Model + PMD    Full + PMD: Natural Menopause   Full + PMD: Surgical Menopause             
MHT Status Estimate N 95% CI P-value Estimate N 95% CI P-value Estimate N 95% CI P-value          
Never 0 (ref) 702    0 (ref) 476    0 (ref) 199              
Past 0.06 334 -0.05 0.17 0.281 0.10 190 -0.04 0.24 0.171 -0.13 128 -0.32 0.07 0.199          
Estrogen <5y 0.15 176 0.01 0.29 0.036 0.22 36 -0.13 0.56 0.218 0.03 148 -0.15 0.20 0.777          
Estrogen >5y 0.05 351 -0.06 0.16 0.402 0.37 33 0.07 0.67 0.017 -0.11 316 -0.26 0.04 0.166          
Est + Prog <5y 0.19 192 0.05 0.33 0.007 0.26 159 0.10 0.42 0.002 -0.15 22 -0.51 0.20 0.392          
Est + Prog >5y 0.14 148 -0.01 0.29 0.074 0.26 108 0.08 0.44 0.004 -0.33 34 -0.64 -0.01 0.043          
Other -0.03 83 -0.22 0.16 0.771 0.05 46 -0.19 0.30 0.679 -0.22 32 -0.55 0.12 0.201          
P-trend <0.01     <0.01     <0.01                
 
 
Supplementary Table 1. Participant Characteristics, V75 High Resolution  
V75 High 
   MHT Status    
Never (N=247) Past (N=119) Estrogen <5y (N=90) Estrogen >5y (N=194) Est. & Progest. <5y (N=98) Est. & Progest. >5y (N=76) Other (N=38)  
Age at mammogram, years 56.4 (8.5) 62.0 (9.1) 51.3 (6.9) 55.6 (8.4) 53.6 (5.7) 56.6 (7.9) 54.9 (6.3) 
BMI at mammogram 25.7 (4.9) 25.2 (5.1) 26.2 (5.0) 24.9 (4.5) 24.6 (4.0) 24.4 (4.7) 24.4 (3.8) 
Non-white, % 2.4 8.4 2.2 3.6 2.0 6.6 2.6 
Type of menopause        
. 2.4 4.2 . 0.52 2.0 6.6 5.3 
Natural 58.8 68.9 5.6 6.7 88.8 72.4 57.9 
Surgical 38.9 26.9 94.4 92.8 9.2 21.1 36.8 
Family history of breast cancer        
No 87 82.4 91.1 91.2 96.9 88.2 89.5 
Yes 13 17.6 8.9 8.8 3.1 11.8 10.5 
History of benign breast disease        
No 74.9 76.5 77.8 71.3 72.5 76.3 73.7 
Yes 25.1 23.5 22.2 28.9 27.6 23.68 26.3 
Age at menarche, years 12.2 (1.7) 12.6 (1.4) 12.4 (1.5) 12.7 (1.3) 12.4 (1.3) 13.0 (1.5) 12.4 (1.3) 
Age at menopause, years 45.9 (7.4) 46.7 (6.8) 42.0 (7.1) 40.4 (6.5) 48.2 (4.5) 43.9 (7.4) 44.4 (7.8) 
Parity 
3.1 (1.5) 3.1 (1.5) 2.5 (1.3) 2.7 (1.3) 2.7 (1.3) 2.7 (1.4) 3.0 (1.7) Mean parity 
nulliparous 11.3 10.9 12.2 9.8 14.3 17.1 13.2 
1 7.3 8.4 14.4 12.9 14.3 14.5 13.2 
2 28.3 26.9 37.8 31.4 24.5 30.3 29.0 
3 26.7 26.9 23.3 27.3 28.6 19.7 13.2 
4+ 26.3 26.9 12.2 18.6 18.4 18.4 31.6 
Total breastfeeding        
<1 month 31.6 35.3 30.0 37.6 28.6 34.2 31.6 
1-6 months 20.2 26.1 25.6 19.1 25.5 9.2 15.8 
7-12 months 13 9.2 6.7 11.3 13.3 10.5 10.5 
>=13 months 23.9 21 27.8 22.7 20.4 29.0 31.6 
. 11.3 8.4 10.0 9.3 12.2 17.1 10.5 
Age at first birth, years 25.2 (3.2) 25.1 (3.0) 24.2 (3.0) 24.1 (3.7) 25.4 (4.1) 25.4 (4.1) 25.0 (2.9) 
V75, high -0.52 (0.90) -0.43 (0.95) -0.29 (0.87) -0.24 (1.00) -0.08 (1.01) -0.02 (0.76) -0.21 (0.89) 
Percent memmographic density 27.12 (17.02) 24.49 (13.89) 32.03 (17.53) 29.79 (15.55) 32.65 (16.52) 31.53 (15.83) 31.02 (17.19) 
 
 
Supplementary Table 2: Sensitivity Analyses for Age + BMI Model, Multivariable Model   
           V75 High              
 Age + BMI v75 high    Age + BMI: Natural Menopause   Age + BMI: Surgical Menopause   Age + BMI v75 high: Low PMD   Age + BMI v75 high: High PMD   
MHT Status Estimate N 95% CI P-value Estimate N 95% CI P-value Estimate N 95% CI P-value Estimate N 95% CI P-value Estimate N 95% CI P-value 
Never 0 (ref) 247    0 (ref) 476    0 (ref) 199    0 (ref) 415    0 (ref) 287    
Past 0.17 119 -0.03 0.37 0.097 0.35 190 0.11 0.58 0.004 -0.26 128 -0.64 0.12 0.185 -0.01 188 -0.24 0.22 0.919 0.22 146 -0.05 0.49 0.110 
Estrogen <5y 0.17 90 -0.05 0.39 0.128 -0.12 36 -0.89 0.65 0.766 -0.01 148 -0.28 0.25 0.914 0.14 66 -0.15 0.43 0.348 0.11 110 -0.15 0.37 0.421 
Estrogen >5y 0.22 194 0.05 0.39 0.010 0.64 33 0.15 1.13 0.010 -0.02 316 -0.25 0.21 0.879 -0.11 158 -0.33 0.11 0.338 0.26 193 0.05 0.46 0.016 
Est + Prog <5y 0.33 98 0.12 0.54 0.002 0.52 159 0.28 0.76 <.001 -0.24 22 -0.85 0.38 0.454 0.04 70 -0.25 0.33 0.793 0.37 122 0.12 0.62 0.003 
Est + Prog >5y 0.43 76 0.20 0.66 <.001 0.62 108 0.35 0.89 <.001 0.03 34 -0.45 0.51 0.917 0.35 63 0.05 0.66 0.023 0.34 85 0.07 0.62 0.014 
Other 0.21 38 -0.10 0.51 0.180 0.40 46 0.01 0.78 0.046 -0.07 32 -0.58 0.44 0.796 0.00 35 -0.42 0.41 0.983 0.24 48 -0.12 0.60 0.183 
P-trend <0.01     <0.01     <0.01     <0.01     <0.01*     
                 
 Full Model v75 high    Full Model: Natural Menopause   Full Model: Surgical Menopause   Full Model v75 high: Low PMD   Full Model v75 high: High PMD   
MHT Status Estimate N 95% CI P-value Estimate N 95% CI P-value Estimate N 95% CI  P-value Estimate N 95% CI  P-value Estimate N 95% CI P-value 
Never 0 (ref) 247    0 (ref) 476    0 (ref) 199    0 (ref) 415    0 (ref) 287    
Past 0.19 119 -0.02 0.40 0.078 0.38 190 0.13 0.63 0.003 -0.34 128 -0.75 0.08 0.112 0.00 188 -0.23 0.24 0.983 0.28 146 -0.02 0.59 0.066 
Estrogen <5y 0.19 90 -0.04 0.42 0.101 -0.20 36 -1.04 0.65 0.650 0.00 148 -0.28 0.28 0.990 0.20 66 -0.10 0.51 0.183 0.05 110 -0.23 0.34 0.715 
Estrogen >5y 0.24 194 0.06 0.41 0.009 0.38 33 -0.14 0.91 0.150 0.01 316 -0.24 0.26 0.918 -0.06 158 -0.29 0.17 0.613 0.22 193 -0.01 0.45 0.056 
Est + Prog <5y 0.22 98 0.00 0.44 0.049 0.40 159 0.15 0.66 0.002 -0.11 22 -0.72 0.50 0.714 0.06 70 -0.24 0.36 0.690 0.21 122 -0.06 0.49 0.122 
Est + Prog >5y 0.38 76 0.13 0.63 0.003 0.55 108 0.26 0.83 <.001 -0.01 34 -0.56 0.53 0.959 0.32 63 -0.01 0.64 0.057 0.26 85 -0.05 0.57 0.096 
Other 0.13 38 -0.19 0.45 0.416 0.30 46 -0.10 0.70 0.137 -0.20 32 -0.76 0.36 0.480 0.00 35 -0.41 0.41 1.000 0.13 48 -0.27 0.53 0.520 
P-trend <0.01     <0.01     <0.01     <0.01     <0.01     
                     
 Full Model + PMD    Full + PMD: Natural Menopause   Full + PMD: Surgical Menopause             
MHT Status Estimate N 95% CI P-value Estimate N 95% CI P-value Estimate N 95% CI P-value          
Never 0 (ref) 247    0 (ref) 476    0 (ref) 199              
Past 0.09 119 -0.09 0.28 0.324 0.25 190 0.02 0.48 0.034 -0.32 128 -0.68 0.03 0.073          
Estrogen <5y 0.10 90 -0.10 0.31 0.315 -0.03 36 -0.81 0.75 0.938 -0.07 148 -0.31 0.17 0.574          
Estrogen >5y 0.09 194 -0.07 0.24 0.292 0.21 33 -0.28 0.69 0.396 -0.11 316 -0.33 0.10 0.293          
Est + Prog <5y 0.12 98 -0.08 0.32 0.240 0.25 159 0.02 0.49 0.036 0.00 22 -0.52 0.52 0.992          
Est + Prog >5y 0.24 76 0.02 0.46 0.034 0.37 108 0.11 0.64 0.006 -0.16 34 -0.63 0.31 0.503          
Other 0.04 38 -0.24 0.33 0.762 0.13 46 -0.24 0.50 0.500 -0.22 32 -0.70 0.26 0.358          
P-trend <0.01     <0.01     <0.01                
